1.Chemotherapy outcome of patients with choriocarcinoma
Mongolian Medical Sciences 2012;159(1):26-30
Background: Choriocarcinoma 15-20 new cases per year diagnosed at National Cancer Center of Mongolia. Due to insufficient necessary new drugs for choriocarcinoma patients, cancer center cannot provide the most useful treatment EMA/CO so patients were treated MAC or metothrexate, Adriamycin and cyclophosphamide. The outcomes of patients with choriocarcinoma treated with combined chemo drugs never been studied in Mongolia.
Goal: To evaluate the results of combined chemotherapy in choriocarcinoma at National Cancer Center of Mongolia.
Methods: Retrospective cohort review of 42 patients with choriocarcinoma who treated with MAC combination chemotherapy at NCC of Mongolia during 2004-2007. Based on MAC ppatients charts we evaluated clinical characteristics, level of HCG during treatment cycles, ultrasound changes and other lab tests.
Results: We treated 42 patients with choriocarcinoma from 2004 through 2007. All patients were treated with MAC combination chemotherapy at NCC. The number of cases with choriocarcinoma is increasing in each year. 37.5% of these patients were aged between 30-34 years old, so it shows maximum incidence occurs during child bearing years. The most common clinical characteristics were 44% bleeding, 32% lower abdominal quadrant pain related to disease stages, 36% cough, and 28% fever. Out of 42 patients 35% of them had lung metastasis which was significantly different than other gynecological cancer metastasis.
Conclusion: MAC combination treatment offers long-term disease-free survival and potential cure in patients with choriocarcinoma. The reported median survival in these group patients is 5 years. Importantly, 56% of patients were lived up to 5 years in remission.
2.Phase III multi-centre open-label randomized controlled trial of selective internal radiation therapy (SIRT) versus Sorafenib in locally advanced hepatocellular carcinoma(SIRveNIB)
Ariunaa Kh ; Sanduijav R ; Bolormaa Ya ; Tuyatsetseg A
Mongolian Medical Sciences 2016;177(3):20-24
Background
This study is a multi-centre, open-label, randomised controlled trial that will compare the impact of
selective internal radiation therapy (SIRT) using SIR-Spheres® yttrium-90 microspheres versus sorafenib
on overall survival in patients with locally advanced hepatocellular carcinoma (HCC). A definitive RCT
comparing the 2 most promising therapies in locally-advanced HCC will impact on outcomes in a large
number of patients and change clinical practice. This will also pave the way for future trials in combined
modality therapies in HCC.
Methods
The study is structured so that patients with locally advanced HCC, who satisfy the study eligibility
criteria, will be randomised to receive either: Treatment Arm A: Oral Sorafenib therapy at a dose of 400
mg b.i.d until disease progression, no further response, complete regression or unacceptable toxicity or
Treatment Arm B: A single administration of SIR-Spheres into the liver targeted at HCC in the liver by
the trans-arterial route.
Results
Twenty patients treated with 90Y-RE and nineteen patients received Sorafenib at our institution from 14
March 2011, and 30 June 2016 were included. Data from 39 consecutive patients were analyzed. The
majority of patients were Child Pugh class B(90%), Barcelona Clinic liver Cancer(BCLC) stage C(58.5%)
and Okuda class I (89.5%). Approximately 71% patients diagnosed in IIIa stage and 70% of patients had
HBV infection. In the analysis for best response, three of 20 patients in the SIRT group (15%) achieved
a partial response 7 of 19 patients (46%) had stable disease, whereas in Sorafenib group, two of 19
patients in the SIRT group (12%) achieved a partial response 9 of 19 patients (39%) had stable disease.
Conclusion
This study shows the potential efficacy of SIR-Spheres and sorafenib. In summary, selective internal
radiation therapy (SIRT) using SIR-Spheres is a promising treatment for well selected patients with
unresectable HCC. Sorafenib is effective for the patients with locally advanced HCC without portal vein
thrombosis (PVT).
3.HOSPITAL BASED 4 WEEK PHYSICAL THERAPY PROGRAM RESULTS AFTER ACUTE MYOCARDIAL INFARCTION
Oirov M ; Ariunaa Kh ; Mungunsuvd N ; Urangerel D
Innovation 2018;12(4):10-13
BACKGROUND: Early physical therapy plays important role in improving functional capacity, activities of daily life, and quality of life after acute myocardial infarction.
OBJECTIVE: We aimed to describe effects of 4 weeks physical therapy program after acute myocardial infarction.
METHODS: In our study, 20 men participated in physical therapy program for 14 days after PCI surgery. The patients were diagnosed with myocardial infarction and aged 56.45±8.1. Their BMI was 27.39±3.61and waist circumference was 98±9.28. Exercise program was scheduled 3 times a week with each session consisting of 34-70% intensity exercises for 60 minutes. Exercise type is aerobic (warming up for 10 minutes, walking, bicycling and cooling down stretch for 10 minutes).
RESULTS: For the 6-minute walking test (p=0.01) there was significant difference between before and after 4 weeks’ exercise program.
CONCLUSION: The hospital based 4 weeks exercise program improved the functional capacity for pci patients.
4.THE STUDY OF FEMALE INFERTILITY WITH ANTI-TPO AND ANTI-TG AUTOIMMUNE DEFICIENCY IN THYROID GLAND
Tuvshibayar N ; Solongo M ; Ariunaa E ; Davaakhuu S ; Khishigjargal U ; Dulguun Kh ; Munkhzol M ; Odkhuu E
Innovation 2018;12(1):35-39
BACKGROUND: According to the World Health Organization (WHO), 10-15% of couples of reproductive age have infertility. According to researcher D. Sukhe (1999), hormonal infertility in the reproductive age of women was 33.6%, which was a large part of the cause of infertility. In recent years, the number of cases of endocrine disorders, including malignancy and sexually transmitted infections, has been increasing year by year. According to WHO reports, thyroid disorders have a prevalence of 49.3% for active reproductive age (30-50). According to the report of the Health Development Center in 2016, since the thyroid disorders are the second most common disease in endocrine gland disease, our study found that the infertility in reproductive age of women can be substantial due to the loss of thyroid gland.
METHODS: The study was carried out by the couple of 20-45 year-olds and modeled as an analytical study model. The questionnaire was used for the couple’s interviews and some of the measurement of body and serum use of TOSOH Corporation AIA-360, Tokyo, Japan. On the serum, anti-TPO and аnti-TG carbohydrates are identified by the Cobas e-411 analyzer under the manufacturer’s accompanying protocol.
RESULTS: 76.7% of women were diagnosed with infertility euthyroid, 0.7% hyperthyroidism, 22.6% hypothyroidism (3.8% with overt hypothyroidism and 18.8% subclinical hypothyroidism). Prevalence of TAI, in 6.7% isolated positive anti-Tg were found, and 14.3% had isolated positive TPO, In 3.7% of cases, both types of autoantibodies were present.
We analysed binary logistic regression for anti-TPO and anti-TG autoantibody in the positive and negative group in past obstetrics history, evidence of positive of anti-TPO and anti-Tg was increased risk of miscarriage 2.2 times (OR = 2.2, p <0.01).
CONCLUSIONS: Women with disorders in our study have high percentage of subclinical hypothyroidism and have higher rate of thyroid autobodies in serum which may be a problem for women with infertility and pregnancy complications due to the loss of thyroid gland. There is a need to develop a principle of recovery and treatment.
5.THE STUDY OF FEMALE INFERTILITY WITH ANTI-TPO AND ANTI-TG AUTOIMMUNE DEFICIENCY IN THYROID GLAND
Tuvshinbayar N ; Badrakh M ; Ariunaa E ; Arigbukh E ; Dulguun Kh ; Munkhzol M ; Odkhuu E
Innovation 2018;12(4):8-13
BACKGROUND. According to the World Health Organization (WHO), 10-15% of couples of reproductive age have infertility. According to researcher D. Sukhe (1999), hormonal infertility in the reproductive age of women was 33.6%, which was a large part of the cause of infertility. In recent years, the number of cases of endocrine disorders, including malignancy and sexually transmitted infections, have been increasing year by year. According to WHO reports, thyroid disorders have a prevalence of 49.3% among active reproductive age (30-50) group. According to the report of the Health Development Center in 2016, since the thyroid disorders are the second most common disease in endocrine gland disease, our study has found that the infertility in reproductive age of women can be substantial due to the loss of thyroid gland.
OBJECTIVE. To study the relationship between the thyroid gland antibodies and female infertility.
MATERIAL AND METHODS. The study was carried out in 20-45 year old couples and was modeled as an analytical study model. The questionnaire was used for the couple’s interviews, antroplogical measurements, and serum was analysed. On the serum, anti-TPO and аnti-TG carbohydrates were identified by the Cobas e-411 analyzer under the manufacturer’s accompanying protocol.
RESULTS. Prevalence of TAI, in 6.7% positive anti-Tg were found, and 14.3% had positive TPO. In 3.7% of cases, both types of autoantibodies were present. We analysed binary logistic regression for anti-TPO and anti-TG autoantibody in the positive and negative group in relation to the past obstetrics history. A=Accoding to the analysis, evidence of positive anti-TPO and anti-Tg increased the risk of miscarriage by 2.2 times (OR = 2.2, p <0.01).
CONCLUSION: Women with infertility in our study have high percentage of subclinical hypothyroidism and have higher rate of thyroid autobodies in serum which could be a problem for women with infertility and pregnancy complications due to the loss of thyroid gland. Thus, there is a need to develop intervention guidelines for recovery and treatment of these types of infertility.